Background: Patients with end-stage renal disease on hemodialysis have excess
cardiovascular disease (CVD) burden with substantially increased CV event rates compared …

Objective Atherosclerosis, which causes cardiovascular disease, is a major cause of death
in hemodialysis (HD) patients. Eicosapentaenoic acid (EPA), an anti-hyperlipidemic agent …

Backgrounds: It is well known that eicosapentaenoic acid (EPA) contributes to secondary
prevention of coronary artery disease. Hemodialysis (HD) patients have a high incidence of …

Eicosapentaenoic acid (EPA)/arachidonic acid (AA) ratio showed inverse associations with
cardiovascular disease (CVD) in general population. However, this has not been examined …

Background Unlike the n-6 polyunsaturated fatty acid (PUFA) arachidonic acid (AA), n-3-
PUFAs such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) appear to …

Background. We previously reported that haemodialysis patients have suboptimal blood
levels of the cardioprotective omega-3 polyunsaturated fatty acids (n-3 PUFA) …

Background and Objectives: Omega-3 fatty acids have potent lipid-lowering and antiplatelet
effects; however, randomized controlled trials have yet to examine the effect of high-dose …

BACKGROUND: At present, it is discussed whether omega-3 fatty acids show anti-
inflammatory, antithrombogenic, and antiatherosclerotic effects, also in patients with chronic …

Background: Blood levels of the anti-inflammatory and cardioprotective omega-3
eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids are determined primarily …

Background. Soy protein ameliorates rat polycystic kidney disease with concomitant renal
enrichment of ω3-polyunsaturated fatty acids. A study was conducted to examine the effects …